Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19

Juan G Ripoll, Sidna M Tulledge-Scheitel, Anthony A Stephenson, Shane Ford, Marsha L Pike, Ellen K Gorman, Sara N Hanson, Justin E Juskewitch, Alex J Miller, Solomiia Zaremba, Erik A Ovrom, Raymund R Razonable, Ravindra Ganesh, Ryan T Hurt, Erin N Fischer, Amber N Derr, Michele R Eberle, Jennifer J Larsen, Christina M Carney, Elitza S TheelSameer A Parikh, Neil E Kay, Michael J Joyner, Jonathon W Senefeld

Research output: Contribution to journalArticlepeer-review


Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients with immunosuppression have poor immunogenic responses to COVID-19 vaccines and remain at high risk of infection with SARS-CoV-2 and hospitalization. In addition, monoclonal antibody therapy is limited by the emergence of novel SARS-CoV-2 variants that have serially escaped neutralization. In this context, there is interest in understanding the clinical benefit associated with COVID-19 convalescent plasma collected from persons who have been both naturally infected with SARS-CoV-2 and vaccinated against SARS-CoV-2 ("vax-plasma"). Thus, we report the clinical outcome of 386 immunocompromised outpatients who were diagnosed with COVID-19 and who received contemporary COVID-19-specific therapeutics (standard-of-care group) and a subgroup who also received concomitant treatment with very high titer COVID-19 convalescent plasma (vax-plasma group) with a specific focus on hospitalization rates. The overall hospitalization rate was 2.2% (5 of 225 patients) in the vax-plasma group and 6.2% (10 of 161 patients) in the standard-of-care group, which corresponded to a relative risk reduction of 65% (P = 0.046). Evidence of efficacy in nonvaccinated patients cannot be inferred from these data because 94% (361 of 386 patients) of patients were vaccinated. In vaccinated patients with immunosuppression and COVID-19, the addition of vax-plasma or very high titer COVID-19 convalescent plasma to COVID-19-specific therapies reduced the risk of disease progression leading to hospitalization.IMPORTANCEAs SARS-CoV-2 evolves, new variants of concern (VOCs) have emerged that evade available anti-spike monoclonal antibodies, particularly among immunosuppressed patients. However, high-titer COVID-19 convalescent plasma continues to be effective against VOCs because of its broad-spectrum immunomodulatory properties. Thus, we report clinical outcomes of 386 immunocompromised outpatients who were treated with COVID-19-specific therapeutics and a subgroup also treated with vaccine-boosted convalescent plasma. We found that the administration of vaccine-boosted convalescent plasma was associated with a significantly decreased incidence of hospitalization among immunocompromised COVID-19 outpatients. Our data add to the contemporary data providing evidence to support the clinical utility of high-titer convalescent plasma as antibody replacement therapy in immunocompromised patients.

Original languageEnglish (US)
Article numbere0040024
Pages (from-to)e0040024
Issue number5
Early online dateApr 11 2024
StatePublished - May 8 2024


  • antibody therapy
  • immunocompromised hosts
  • SARS-CoV-2

ASJC Scopus subject areas

  • Virology
  • Microbiology


Dive into the research topics of 'Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19'. Together they form a unique fingerprint.

Cite this